Clinical Trials

A summary of our ongoing
clinical trials can be found below

Clinical trials are a part of a carefully planned and legally required process to move a potential new drug from the discovery process through to market availability. Our ongoing clinical trial programs are outlined below.


Not Currently Enrolling

Our global Phase III program aims to differentiate ridinilazole from vancomycin, the current standard of care for C. difficile infection.  The program is designed to determine the safety and efficacy of ridinilazole for use as first-line therapy for the treatment of initial and recurrent C. difficile infection.

This effort is funded in part with federal funds of up to $72.5 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, under contract number HHSO100201700014C.

For our latest update related to the Phase III program, please refer to our press release dated August 11, 2021.

Ri-CoDIFy 3

Currently Enrolling

Our Phase III program includes an additional study to determine the safety of ridinilazole as compared to vancomycin, the current standard of care for C. difficile infection, in adolescents 12 through 17 years of age. The trial is expected to enroll approximately 40 patients.

For our information on, please visit Ri-CoDIFy 3.

Access to Medicines

Running clinical trials that can support regulatory approvals is the best way to ultimately ensure wide access for patients to our drug candidates. All of our efforts have been and are, therefore, focused on conducting rigorous clinical trials to establish the safety and potential clinical benefits these candidates may have. At this point in the development, we cannot support any use of our drug candidates outside of clinical trials.